

# Antecedent Administration of Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for SARS-CoV-2 (COVID-19)

**Running title:** *Palazzuoli et al.; Antecedent RAASi in COVID-19*

Alberto Palazzuoli MD, PhD, FESC<sup>1</sup>, Massimo Mancone PhD,<sup>2</sup> Gaetano M. De Ferrari MD,<sup>3</sup> Giovanni Forleo MD,<sup>4</sup> Gioel G. Secco MD, PhD,<sup>5</sup> Gaetano M Ruocco MD,<sup>6</sup> Fabrizio D'Ascenzo MD, PhD,<sup>3</sup> Silvia Monticone MD,<sup>7</sup> Anita Paggi MD,<sup>8</sup> Marco Vicenzi MD,<sup>9</sup> Anna G Palazzo MD,<sup>10</sup> Maurizio Landolina MD,<sup>11</sup> Erika Taravelli MD,<sup>11</sup> Guido Tavazzi MD PhD,<sup>12</sup> Francesco Blasi MD,<sup>13</sup> Fabio Infusino MD,<sup>2</sup> Francesco Fedele MD,<sup>2</sup> Francesco G De Rosa MD<sup>14</sup> Michael Emmett, MD,<sup>15</sup> Jeffrey M. Schussler, MD,<sup>15 16 17</sup> Kristen M. Tecson, PhD,<sup>15 16 17</sup> Peter A. McCullough, MD, MPH<sup>15</sup>

16 17

<sup>1</sup>Cardiovascular Diseases Unit, Department of Medical Sciences, AOUS Le Scotte Hospital University of Siena, Siena, Italy; <sup>2</sup>Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza, University of Rome, Roma, Italy; <sup>3</sup>Cardiology, Department of Medical Science University of Turin, Città della Salute e Della Scienza Le Molinette Hospital Torino, Torino Italy; <sup>4</sup>Section Head Electrophysiology and Cardiac Pacing Azienda Ospedaliera - Polo Universitario - "Luigi Sacco", Milano, Italy; <sup>5</sup>Interventional Cardiology and Cardiac Surgery Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy; <sup>6</sup>Cardiology Division, Regina Montis Regalis Hospital Mondovì, Cuneo, Italy; <sup>7</sup>Division of Internal Medicine, Department of Medical Sciences University of Turin, Turin, Italy; <sup>8</sup>Interventional Cardiology Department of Internal Medicine ASSST Nord Milano E Bassini Hospital Cisanello Balsamo, Milan, Italy; <sup>9</sup>Cardiovascular Disease Unit, Department of Internal Medicine, University of Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy; <sup>10</sup>Infectious Disease, Department of Medical Sciences, University of Torino, AOU Città della salute e della Scienza, Torino, Italy; <sup>11</sup>Cardiology Division, Ospedale Maggiore of Crema, Crema, Italy; <sup>12</sup>Intensive Care, University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; <sup>13</sup>Respiratory Unit and Adult Cystic Fibrosis Center, Department of Internal Medicine, University of Milano, Fondazione IRCCS Ca'

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1161/jaha.120.017364](https://doi.org/10.1161/jaha.120.017364)

This article is protected by copyright. All rights reserved

Granda Ospedale Maggiore Policlinico, Milano, Italy; <sup>14</sup>Infectious Disease, Department of Medical Sciences, University of Torino, AOU Città della salute e della Scienza, Torino, Italy; <sup>15</sup>Baylor University Medical Center, Dallas, TX; <sup>16</sup>Baylor Scott and White Heart and Vascular Hospital, Dallas, TX; <sup>17</sup>Baylor Heart and Vascular Institute, Dallas, TX

**Corresponding Author:**

Peter A. McCullough, MD, MPH

Baylor University Medical Center

621 N Hall Street, Suite H-030, Dallas, TX 75226

Phone: 248.444.6905/Fax: 214.820.7393/Email: peteramccullough@gmail.com

**Journal Subject Terms:** ACE/Angiotension Receptors/Renin Angiotensin System

## Abstract

**Background:** SARS-CoV-2 (COVID-19) utilizes the angiotensin converting enzyme-2 (ACE-2) receptor to enter human cells. Angiotensin converting enzyme inhibitors (ACEI) and angiotensin II receptor antagonists (ARB) are associated with ACE-2 upregulation. We hypothesized that antecedent use of ACEI/ARB may be associated with mortality in COVID-19.

**Methods and Results:** We used the Coracle registry, which contains data of hospitalized COVID-19 patients in 4 regions of Italy, and restricted analyses to those  $\geq 50$  years of age. The primary outcome was in-hospital mortality. Among these 781 acutely ill patients, 133 (17.0%) used an ARB and 171 (21.9%) used an ACEI. While neither sex nor smoking status differed by user groups, patients on ACEI/ARB tended to be older and more likely to have hypertension, diabetes mellitus, and congestive heart failure. The overall mortality rate was 15.1% (118/781) and increased with age ( $P_{\text{Trend}} < 0.0001$ ). The crude odds ratios (ORs) for death for ACEI users and ARB users were 0.98, 95% confidence interval (CI): 0.60-1.60,  $p=0.9333$ , and 1.13, 95% CI: 0.67-1.91,  $p=0.6385$ , respectively. After adjusting for age, hypertension, diabetes mellitus, and congestive heart failure, antecedent ACEI administration was associated with reduced mortality (OR: 0.55, 95% CI: 0.31-0.98,  $p=0.0436$ ); a similar, but weaker trend was observed for ARB administration (OR: 0.58, 95% CI: 0.32-1.07,  $p=0.0796$ ).

**Conclusions:** In those aged  $\geq 50$  years hospitalized with COVID-19, antecedent use of ACEI was independently associated with reduced risk of inpatient death. Our findings suggest the protective role of renin-angiotensin-aldosterone system inhibition in patients with high cardiovascular risk affected by COVID-19.

**Key words:** SARS-CoV-2 (COVID-19), renin-angiotensin converting enzyme inhibitor, angiotensin converting enzyme inhibitor, angiotensin converting enzyme-2, hospitalization, mortality

## **Clinical Perspective**

### **What is new?**

- In patients hospitalized with COVID-19, antecedent use of angiotensin converting enzyme inhibitors was associated with decreased odds of in-patient mortality, after adjusting for comorbidities.

### **What are the clinical implications?**

- Current users of renin-angiotensin-aldosterone inhibitors should continue their use during the COVID-19 pandemic.

### **Non-standard Abbreviations and Acronyms**

ACE-2	angiotensin converting enzyme-2
ACEI	angiotensin converting enzyme inhibitors
ARB	angiotensin II receptor antagonists
ARDS	adult respiratory distress syndrome
CI	confidence interval
COVID-19	SARS-CoV-2
OR	odds ratio

In the midst of the SARS-CoV-2 (COVID-19) pandemic there has been considerable interest and speculation concerning the prior administration of renin-angiotensin-aldosterone system inhibitors given the understanding that the coronavirus family utilizes the angiotensin converting enzyme 2 (ACE-2) receptor for entry into human somatic cells. [1, 2] One line of reasoning has been that more ACE-2 receptors available for viral entry would lead to more severe and possibly fatal infections. An alternative viewpoint is that the ACE-2 receptor could be functioning in a protective

manner despite facilitating viral entry, and that COVID-19 target mediated destruction and reduction of receptor density could be part of the pathogenesis of the adult respiratory distress syndrome (ARDS) associated with acute infection. Piecing together observations from preclinical models it has been postulated that children have a relative upregulation of ACE-2 and potentially greater pulmonary endothelial density of ACE-2 expression. [3] It is notable that the rates of symptomatic and fatal cases of COVID-19 are progressively lower at younger ages. [4] Conversely, the elderly and those who are smokers are believed to have lesser densities of ACE-2 receptors in the lungs and lower inferred levels of circulating ACE-2. [5, 6] Experimental data in ARDS models suggest that ACE-2 is downregulated and some of its peptide products (Ang 1-7) are consequently diminished, and thus vascular endothelial protection is lost in the development of ARDS. [7, 8, 9] Soluble ACE-2 has been administered experimentally and appears to lessen pathophysiological correlates of ARDS in vitro and in animal models. [10, 11, 12]

In humans, long-standing administration of angiotensin converting enzyme inhibitors (ACEI) and or angiotensin II receptor antagonists/blockers (ARB) leads to an upregulation of ACE-2 on the surface of vascular endothelial cells and possibly other somatic cell lines. This may be more pronounced with ACEI since angiotensin II, the substrate for ACE-2 is diminished. By these lines of thinking, ACEI/ARB may be a “double-edged sword” with either protective or harmful effects on outcomes in older individuals and those with multiple comorbidities when hospitalized for COVID-19. [13, 14] In particular, AlGhatrif and colleagues hypothesized that the increase in ACE-2 levels with RAAS inhibition is likely to be beneficial for vulnerable individuals with COVID-19 who have reduced ACE-2 expression, e.g. older individuals, hypertensives, and/or diabetics. [15] Several professional societies have recommended continuing ACEI/ARB in patients with COVID-19, but acknowledge a lack of data. [16, 17] Hence, we sought to determine the association between ACEI/ARB use and inpatient mortality among COVID-19 patients aged 50 years or older using a registry of patients with acute COVID-19 illness resulting in hospitalization in Italy.

## **Methods**

### *Data*

The data and materials used for these analyses will not be made available. We used the Coracle (epidemiology, clinical characteristics, and therapy in real life patients affected by Sars-Cov-2) multi-center registry, which contains data of hospitalized COVID-19 patients from participating referral centers in Piedmont, Lombardy, Tuscany, and Lazio regions of Italy, to perform this analysis. Patients were included in the registry if they were at least 18 years old, hospitalized with COVID-19 (confirmed using nose or throat swab testing with real-time reverse transcription polymerase chain reaction) on or after February 22, 2020, and had a known mortality or discharge status as of April 1, 2020. We chose to restrict this analysis to patients aged 50 years or greater due to the significant increase in mortality observed at this age cutoff in previous COVID-19 publications, as well as for clinical indications of ACEI/ARB. [4] At hospital admission, patients gave their written consent to data collection anonymously. This work was approved by the ethical committee of Turin (Coracle registry: epidemiology clinical characteristics and therapy in real life patients affected by SARS-CoV-2).

### *Statistical Analysis*

The only continuous variable, age, was skewed and is presented as median [quartile 1, quartile 3]. In order to more clearly evaluate risk, we categorized age based on decade of life as follows: 50 – 59, 60 – 69, 70 – 79, and 80+. Categorical variables were reported as counts and proportions as appropriate. Differences in patient characteristics between patients treated with ACEI, ARB, and those not taking ACEI/ARB were assessed via the Kruskal-Wallis Test and Chi-Square test, respectively. We utilized the Cochran-Armitage Trend Test to assess for a trend between age group and mortality rate. We examined crude odds ratios for death based on ACEI/ARB use, as well as adjusted odds ratios according to the pre-specified adjustment for age decade, history of hypertension (defined as blood pressure > 140/90 mmHg), diabetes mellitus, and congestive heart failure via multivariable logistic regression. Analyses were performed using SAS version 9.4 (Cary, NC)

### **Results**

There were 956 patient records reviewed and 175 (18.3%) were excluded due to age < 50 years. Hence, 781 patients were included in this analysis. Upon admission, 477 (61.1%) patients were not using ACEI/ARB, 133 (17.0%) were using an ARB, and 171 (21.9%) were using an ACEI. While neither sex nor smoking status differed significantly by ACEI/ARB user groups, patients using ACEI/ARB tended to be older and more likely to have hypertension, diabetes mellitus, and congestive heart failure than those not using ACEI/ARB (Table 1). Additionally, a total of 225 (28.8%) and 107 (13.8%) patients were treated in the intensive care unit and received invasive ventilation, respectively; neither was associated with antecedent ACEI/ARB use ( $p = 0.2463$ ,  $p = 0.6089$ ).

The overall mortality rate was 15.1% (118/781) and an increasing trend with age was detected ( $P_{\text{Trend}} < 0.0001$ , Figure 1). Death by specific subgroups is shown in Figure 2. Overall, the crude odds ratios for death for those who used ACEI and those who used ARB at admission compared to no ACEI/ARB were 0.98 (95% CI: 0.60 – 1.60,  $p = 0.9333$ ) and 1.13 (95% CI: 0.67 – 1.91,  $p = 0.6385$ ), respectively. Among diabetic patients, the crude odds ratios for death for those who used ACEI and those who used ARB at admission compared to no ACEI/ARB were 2.05 (95% CI: 0.70 – 5.98,  $p = 0.1884$ ) and 2.02 (95% CI: 0.62 – 6.63,  $p = 0.2445$ ), respectively. Among hypertensive patients, the crude odds ratios for death for those who used ACEI and those who used ARB at admission compared to no ACEI/ARB were 0.49 (95% CI: 0.28 – 0.86,  $p = 0.0125$ ) and 0.57 (95% CI: 0.32 – 1.01,  $p = 0.0552$ ), respectively. Among patients with congestive heart failure, the crude odds ratio for death for those who used ACEI at admission compared to no ACEI/ARB was 0.61 (95% CI: 0.16 – 2.3,  $p = 0.4721$ ); there were 0 deaths of the 16 congestive heart failure treated with ARB.

In unadjusted analyses, neither ACEI nor ARB significantly changed the odds of death compared to no ACEI/ARB use (Figure 3). However, after adjusting for age decade, hypertension, diabetes mellitus, and congestive heart failure, ACEI decreased the odds of death by approximately 45% (odds ratio (OR): 0.553, 95% confidence interval (CI): 0.311-0.983,  $p = 0.0436$ ). The large shift in ORs is primarily attributed to the adjustment of hypertension. Specifically, although only 57.9% of the patients in this analysis were hypertensive, they accounted for 74.6% of the deaths. Further, the mortality rates for hypertensive patients were 15.1%, 16.9%, and 26.5% for ACEI users, ARB users, and no RAASi users, respectively. ARB use did not significantly change the odds of death compared

to patients using neither ACEI nor ARB, under the same adjustment (OR: 0.586, 95% CI: 0.322-1.065,  $p = 0.0796$ ). The Hosmer-Lemeshow test yielded a  $p$ -value of 0.8093, indicating the model fit the data well. Additionally, the area under the receiver operating characteristic curve was 0.737, indicating that the model had good ability to discriminate inpatient mortality from survival.

## Discussion

We found that among individuals aged  $\geq 50$  years hospitalized with COVID-19 infection, that antecedent ACEI administration was associated with a considerably reduced case fatality rate after adjusting for age, hypertension, diabetes, and heart failure. Because of the predisposition of these comorbidities to mortality, only after adjustment did the protective effect of ACEI usage become apparent. Because it is common that hypotension and likely withdrawal of ACEI (or ARB) occurred in the sequence of events before death in COVID-19 infections, we would infer it is the antecedent chronic use and not the acute administration of these agents that had an effect.

Our findings are in line with Lui and coworkers who reported on 46 patients over age 65 with hypertension hospitalized with COVID-19, that both ACEI and ARB were associated with unadjusted reduced odds for mortality, but the point estimates were unstable and only ARB use had an adjusted  $p$ -value of 0.046. [18] The finding is reassuring in that in older individuals with common and compelling indications for ACEI/ARB use including chronic kidney disease and heart failure, there was no excessive risk of mortality with previous chronic administration and supports most professional societies that have advised that patients on ACEI/ARB be continued on therapy in the setting of COVID-19. [19]

Our study raises many questions for the current COVID-19 pandemic. Could chronic ACEI/ARB use be protective against initial infection or reduce the severity of COVID-19 pneumonia? Large population studies including the large fraction of COVID-19 patients who shelter at home and are not hospitalized will need to be performed. Would administration of ACEI/ARB in hospital be protective against the development of ARDS? For this question, daily ACEI/ARB administration is needed or preferably a randomized trial recruiting hospitalized subjects. Finally, do

these data suggest along with the body of information on ACE-2 and COVID-19, that therapeutic upregulation of ACE-2 or soluble ACE-2 be a therapeutic strategy suitable for other agents or possibly recombinant ACE-2?

Our study has all the limitations of retrospective observational cohort studies performed with limited information in the setting of critical pandemic. We lacked clarity on the primary indication of ACEI/ARB prescription, dose, duration, and tolerability with respect blood pressure and azotemia. We did not have information on the choice of ACEI versus ARB and whether or not ARB treated patients were more likely to be ACEI intolerant. Additionally, other variables of interest, such as body mass index, or measures of ACE-2 activity or its genetic determinants were not available for study. Further, the relatively small sample size could have hindered the ability to detect an association between antecedent ARB administration and inpatient mortality, as its point estimate was similar to that of ACEI's; in an adjusted pooled analysis comparing patients taking either ACEI or ARB against those taking neither ACEI nor ARB revealed an OR: 0.568, 95% CI: 0.347-0.928, and  $p = 0.0239$ . Lastly, our data may have limited generalizability due to the relatively homogeneous nature of the Italian population studied. Despite these limitations, the Coracle registry provides a representation of patients from regions of Italy that experienced very high levels of viral spread, as well as those that were less affected, likely due to lockdown.

In summary, antecedent use of ACEI in patients aged 50 and older hospitalized with COVID-19 was associated with a reduced risk of mortality after adjustment for common indications for ACEI/ARB administration. Future research is urgently needed for better understanding on how the renin angiotensin system and its related pharmacological therapies influence the frequency, severity, and outcomes related to COVID-19 infection.

**Acknowledgments:** We are indebted to the following individuals for their contribution to this work: Francesco Mojoli, MD: Intensive Care University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Federico Franchi, Alex Di Nizio AOUS Le Scotte Hospital, University of Siena Italy, Marco Schiavone e Gianfranco Mitacchione, Azienda Ospedaliera - Polo Universitario - "Luigi Sacco" Milano Italy, Gabriella D'Etterre, Giancarlo Ceccarelli, Claudio Mastroianni Department of

public health and infectious diseases, La Sapienza, University of Rome, Italy, Paolo Severino, Lucia Ilaria Birtolo Department of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Sapienza, University of Rome, Italy, Francesco Pugliese, Franco Ruberto, Francesco Alessandri Department of General Surgery, Surgical Specialities "Paride Stefanini" Rome Italy, Maria Chiara Colaiacomo and Gaia Cartocci, Department of Radiological, Oncological, and Pathological Anatomy Sciences, Sapienza University of Rome, Italy, Alessio Mattei Division of Pneumology University of Torino, AOU Città della salute e della Scienza, Torino, Italy, Monica Andriani Division of Cardiology University of Torino, AOU Città della salute e della Scienza, Torino, Italy.

**Sources of Funding:** None.

**Disclosures:** None.

#### **References:**

1. Lin HX, Feng Y, Wong G, Wang L, Li B, Zhao X, Li Y, Smaill F, Zhang C. Identification of residues in the receptor-binding domain (RBD) of the spike protein of human coronavirus NL63 that are critical for the RBD-ACE2 receptor interaction. *J Gen Virol.* 2008;89:1015-1024.
2. Lo KB, McCullough PA, Rangaswami J. Antihypertensive drugs and risk of COVID-19? *Lancet Respir Med.* 2020; S2213-2600:30156-30159.
3. Colafella KM, Hilliard LM, Denton KM. Epochs in the depressor/pressor balance of the renin-angiotensin system. *Clin Sci (Lond).* 2016;130:761-771.
4. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. *JAMA.* 2020;323:1775-1776.
5. Fernández-Atucha A, Izagirre A, Fraile-Bermúdez AB, Kortajarena M, Larrinaga G, Martínez-Lage P, Echevarría E, Gil J. Sex differences in the aging pattern of renin-angiotensin system serum peptidases. *Biol Sex Differ.* 2017;8:5.

6. Yuan YM, Luo L, Guo Z, Yang M, Ye RS, Luo C. Activation of renin-angiotensin-aldosterone system (RAAS) in the lung of smoking-induced pulmonary arterial hypertension (PAH) rats. *J Renin Angiotensin Aldosterone Syst.* 2015;16:249-253.
7. Rockx B, Baas T, Zornetzer GA, Haagmans B, Sheahan T, Frieman M, Dyer MD, Teal TH, Proll S, van den Brand J, et al. Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory syndrome coronavirus infection. *J Virol.* 2009;83:7062-7074.
8. Wösten-van Asperen RM, Lutter R, Specht PA, Moll GN, van Woensel JB, van der Loos CM, van Goor H, Kamlic J, Florquin S, Bos AP. Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist. *J Pathol.* 2011;225:618-627.
9. Kuba K, Imai Y, Penninger JM. Angiotensin-converting enzyme 2 in lung diseases. *Curr Opin Pharmacol.* 2006;6:271-276.
10. Glowacka I, Bertram S, Herzog P, Pfefferle S, Steffen I, Muench MO, Simmons G, Hofmann H, Kuri T, Weber F, et al. Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63. *J Virol.* 2010;84:1198-205.
11. Battle D, Wysocki J, Satchell K. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? *Clin Sci (Lond).* 2020;134:543-545.
12. Trembl B, Neu N, Kleinsasser A, Gritsch C, Finsterwalder T, Geiger R, Schuster M, Janzek E, Loibner H, Penninger J, et al. Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced lung injury in piglets. *Crit Care Med.* 2010;38:596-601.
13. Wang K, Gheblawi M, Oudit GY. Angiotensin Converting Enzyme 2: A Double-Edged Sword. *Circulation.* 2020. Mar 26 [Epub ahead of print].
14. Guo J, Huang Z, Lin L, Lv J. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory

Syndrome Coronavirus 2 Infection. *J Am Heart Assoc.* 2020;9:e016219. doi: 10.1161/JAHA.120.016219.

15. AlGhatrif M, Cingolani O, Lakatta EG. The Dilemma of Coronavirus Disease 2019, Aging, and Cardiovascular Disease: Insights From Cardiovascular Aging Science. *JAMA Cardiol.* 2020;5:747-748.
16. Bavishi C, Maddox TM, Messerli FH. Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers. *JAMA Cardiol.* 2020;5:745-747.
17. Sommerstein R, Kochen MM, Messerli FH, Gräni C. Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect? *J Am Heart Assoc.* 2020;9:e016509. doi: 10.1161/JAHA.120.016509.
18. Lui Y. Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients. *medRxiv* preprint doi: <https://doi.org/10.1101/2020.03.20.20039586>.
19. Talreja H, Tan J, Dawes M, Supershad S, Rabindranath K, Fisher J, Valappil S, van der Merwe V, Wong L, van der Merwe W, et al. A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019). *N Z Med J.* 2020;133:85-87.

**Table 1. Characteristics of patients in Coracle registry aged ≥ 50 years hospitalized for COVID-19.**

Characteristic	Renin-Angiotensin-Aldosterone System Inhibition				P-value
	Overall (n = 781)	None (n = 477)	ARB (n = 133)	ACEI (n = 171)	
Age (years)	69 [60, 78.5]	66 [58, 78]	73 [65, 80]	72 [63.7, 77]	<0.0001
Age category (years)					<0.0001
50 - 59	194 (24.8%)	150 (31.5%)	17 (12.8%)	27 (15.8%)	
60 - 69	205 (26.2%)	122 (25.6%)	35 (26.3%)	48 (28.1%)	
70 - 79	204 (26.1%)	99 (20.8%)	46 (34.6%)	59 (34.5%)	
80+	178 (22.8%)	106 (22.2%)	35 (26.3%)	37 (21.6%)	
Sex (male)	498 (63.8%)	305 (63.9%)	83 (62.4%)	110 (64.3%)	0.9342
History of hypertension <sup>2</sup>	451 (57.9%)	155 (32.6%)	130 (97.7%)	166 (97.1%)	<.0001
Obstructive lung disease <sup>1</sup>	84 (10.8%)	52 (10.9%)	10 (7.5%)	22 (12.9%)	0.3236
Diabetes mellitus <sup>1</sup>	143 (18.3%)	66 (13.8%)	31 (23.3%)	46 (27.1%)	0.0002
Smoking status <sup>2</sup>					0.2524
Yes	69 (8.9%)	39 (8.2%)	11 (8.3%)	19 (11.1%)	
No	655 (84.1%)	410 (86.1%)	108 (81.8%)	137 (80.1%)	
Former	55 (7.1%)	27 (5.7%)	13 (9.8%)	15 (8.8%)	
Congestive heart failure <sup>2</sup>	67 (8.6%)	31 (6.5%)	16 (12%)	20 (11.7%)	0.0355
Coronary artery disease (ischemia)	104 (13.3%)	46 (9.6%)	28 (21.1%)	30 (17.5%)	0.0005
Beta blocker <sup>1</sup>	174 (22.3%)	82 (17.2%)	42 (31.6%)	50 (29.2%)	<.0001
Calcium channel antagonist <sup>1</sup>	154 (19.7%)	67 (14.1%)	40 (30.1%)	47 (27.5%)	<.0001
Thiazide diuretic <sup>43</sup>	107 (14.5%)	42 (9.3%)	31 (24.6%)	34 (21.3%)	<.0001
Loop diuretic <sup>43</sup>	99 (13.4%)	48 (10.6%)	26 (20.6%)	25 (15.6%)	0.0092
Intensive care unit	225 (28.8%)	130 (27.3%)	37 (27.8%)	58 (33.9%)	0.2463
Invasive ventilation <sup>6</sup>	107 (13.8%)	64 (13.5%)	16 (12.2%)	27 (16%)	0.6089
High flow ventilation without intubation <sup>9</sup>	298 (38.6%)	169 (35.9%)	54 (40.9%)	75 (44.4%)	0.1257

Oxygen low flow <sup>9</sup>	333 (43.1%)	214 (45.4%)	59 (44.7%)	60 (35.5%)	0.0758
------------------------------	-------------	-------------	------------	------------	--------

---

Age is presented as median [quartile 1, quartile 3] and categorical variables are presented as frequency (%).

ARB = angiotensin II receptor antagonist/blocker; ACEI = angiotensin II-converting enzyme inhibitor. The p-value for age was calculated from the Kruskal-Wallis Test. All other p-values were calculated using the Chi-Square test.


Superscripts indicate missing data.

**Figure Legends:**


**Figure 1. Frequency of survival and inpatient death of COVID-19 patients by age group.**

**Figure 2. Inpatient mortality rates by renin-angiotensin-aldosterone system inhibition use before admission for COVID-19.** RAASi = renin-angiotensin-aldosterone system, ACEi = angiotensin converting enzyme inhibitor among those with diabetes, hypertension, and congestive heart failure; ARB = angiotensin II receptor antagonist/blocker.


**Figure 3. Forest plot of odds ratios for death pertaining to renin-angiotensin-aldosterone system inhibitor use.** RAASi = renin-angiotensin-aldosterone system, ACEi = angiotensin converting enzyme inhibitor; ARB = angiotensin II receptor antagonist/blocker; adjusted for age category, hypertension, diabetes mellitus, and congestive heart failure.



jah3\_5651\_f1.jpg



jah3\_5651\_f2.jpg



Adjusted for age group, hypertension, diabetes mellitus, and congestive heart failure.

jah3\_5651\_f3.jpg